Related Experiment Video
Updated: Oct 28, 2025

Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
Published on: March 9, 2015
A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion
Jyoti Sharma1,2,3, Ming Du1,4, Eric Wong5
1Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham (UAB), Birmingham, AL, USA.
Abstract:
Premature termination codons (PTCs) prevent translation of a full-length protein and trigger nonsense-mediated mRNA decay (NMD). Nonsense suppression (also termed readthrough) therapy restores protein function by selectively suppressing translation termination at PTCs. Poor efficacy of current readthrough agents prompted us to search for better compounds. An NMD-sensitive NanoLuc readthrough reporter was used to screen 771,345 compounds. Among the 180 compounds identified with readthrough activity, SRI-37240 and its more potent derivative SRI-41315, induce a prolonged pause at stop codons and suppress PTCs associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells, restoring CFTR expression and function. SRI-41315 suppresses PTCs by reducing the abundance of the termination factor eRF1. SRI-41315 also potentiates aminoglycoside-mediated readthrough, leading to synergistic increases in CFTR activity. Combining readthrough agents that target distinct components of the translation machinery is a promising treatment strategy for diseases caused by PTCs.
Insights
Researchers discovered novel compounds that promote readthrough of premature termination codons (PTCs), restoring protein function. A potent compound, SRI-41315, shows promise for treating genetic diseases like cystic fibrosis by enhancing CFTR expression.
Area of Science:
- Molecular Biology
- Genetics
- Drug Discovery
Background:
- Premature termination codons (PTCs) disrupt protein synthesis and trigger nonsense-mediated mRNA decay (NMD).
- Nonsense suppression therapy aims to restore protein function by readthrough of PTCs, but current agents have limited efficacy.
Purpose of the Study:
- To identify novel compounds with improved nonsense suppression (readthrough) activity.
- To evaluate the efficacy of identified compounds in restoring protein function in cystic fibrosis models.
Main Methods:
- High-throughput screening of 771,345 compounds using an NMD-sensitive NanoLuc readthrough reporter.
- Characterization of lead compounds, including SRI-41315, in human bronchial epithelial cells.
- Assessment of CFTR expression and function restoration.
Main Results:
- Identified 180 compounds with readthrough activity, including SRI-37240 and its derivative SRI-41315.
- SRI-41315 demonstrated prolonged pause at stop codons, suppressed PTCs in cystic fibrosis cells, and restored CFTR expression and function.
- SRI-41315 reduces eRF1 abundance and synergizes with aminoglycosides for enhanced CFTR activity.
Conclusions:
- SRI-41315 is a potent nonsense suppression agent with therapeutic potential for PTC-related diseases.
- Combining readthrough agents targeting different translation machinery components offers a promising therapeutic strategy.
Related Concept Videos
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Leaky Scanning
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
Translation
Translation Produces the Building Blocks of Life
Proteins are...
Improving Translational Accuracy
The Unfolded Protein Response

